Vickovic, Sanja https://orcid.org/0000-0003-0985-9885
Eraslan, Gökcen https://orcid.org/0000-0001-9579-2909
Salmén, Fredrik
Klughammer, Johanna https://orcid.org/0000-0002-3628-9278
Stenbeck, Linnea https://orcid.org/0000-0002-0210-7886
Schapiro, Denis
Äijö, Tarmo https://orcid.org/0000-0002-3008-4634
Bonneau, Richard
Bergenstråhle, Ludvig https://orcid.org/0000-0002-5108-4481
Navarro, José Fernandéz https://orcid.org/0000-0002-4035-5258
Gould, Joshua https://orcid.org/0000-0001-9581-5461
Griffin, Gabriel K. https://orcid.org/0000-0002-4042-6757
Borg, Åke https://orcid.org/0000-0002-5793-132X
Ronaghi, Mostafa
Frisén, Jonas
Lundeberg, Joakim
Regev, Aviv
Ståhl, Patrik L. https://orcid.org/0000-0002-2207-7370
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (2016.0454)
Cancerfonden
Stiftelsen för Strategisk Forskning
Vetenskapsrådet
European Molecular Biology Organization (ALTF 738-2017)
Howard Hughes Medical Institute
Klarman Family Foundation
U.S. Department of Health & Human Services | National Institutes of Health (1OT2OD026673-1)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2ZHP3_181475)
Article History
Received: 12 March 2019
Accepted: 2 August 2019
First Online: 9 September 2019
Competing interests
: F.S., J.F., J.L. and P.L.S. are authors on patents PCT/EP2012/056823 (WO2012/140224), PCT/EP2013/071645 (WO2014/060483) and PCT/EP2016/057355 applied for by Spatial Transcriptomics AB (10x Genomics) covering the described technology. M.R. is employed by Illumina Inc. A.R. is a founder and equity holder of Celsius Therapeutics and an SAB member of Syros Pharmaceuticals and ThermoFisher Scientific.